{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:47Z","timestamp":1787026607337,"version":"build-2736575974"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Post-transplant cyclophosphamide (PTCy) is becoming the standard prophylaxis for graft-versus-host disease (GVHD) in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) and in HLA-matched allo-HCT. Immune reconstitution in the post-transplant setting may influence the graft-versus-tumor (GVT) effect because PTCy has a profound effect on T cell and natural killer cell functions and their reconstitution after allo-HCT. However, many recent studies have shown that the incidence of relapse after allo-HCT with PTCy is comparable to that after conventional allo-HCT. To further improve the outcomes, it is critical to establish a strategy to maintain or effectively induce the GVT effect when using PTCy as a platform for GVHD prophylaxis. However, there is a paucity of studies focusing on the GVT effect in allo-HCT with PTCy. Therefore, focusing on this issue may lead to the establishment of more appropriate strategies to improve transplantation outcomes without exacerbating GVHD, including novel therapies involving cell modification.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1403936","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:27:10Z","timestamp":1718119630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation"],"prefix":"10.3389","volume":"15","author":[{"given":"Hirohisa","family":"Nakamae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32833eaf1b","article-title":"High-dose cyclophosphamide for graft-versus-host disease prevention","volume":"17","author":"Luznik","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13494","article-title":"A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors","volume":"32","author":"Nakamae","year":"2019","journal-title":"Transpl Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1182\/bloodadvances.2022006961","article-title":"Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide","volume":"6","author":"Patterson","year":"2022","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106085","article-title":"\u201cPost-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells","volume":"26","author":"Ritacco","year":"2023","journal-title":"iScience"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.07.023","article-title":"Increased infections and delayed CD4","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101093","article-title":"Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight","volume":"62","author":"McCurdy","year":"2023","journal-title":"Blood Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01403-x","article-title":"GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT","volume":"16","author":"Baron","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: A systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01822-3","article-title":"Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation","volume":"57","author":"Atsuta","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153551","article-title":"Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT","volume":"6","author":"Inoue","year":"2021","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","article-title":"Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exphem.2023.04.003","article-title":"Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model","volume":"123","author":"Makuuchi","year":"2023","journal-title":"Exp Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1038\/s41598-021-92526-z","article-title":"Reduced dose of PTCy followed by adjuvant \u03b1-galactosylceramide enhances GVL effect without sacrificing GVHD suppression","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.028","article-title":"Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: A systematic review and meta-analysis","volume":"25","author":"Arcuri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18862","article-title":"Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000614","article-title":"HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"3","author":"Meybodi","year":"2019","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41409-018-0239-9","article-title":"Haploidentical versus matched donor stem cell transplantation for patients with hematological Malignancies: a systemic review and meta-analysis","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.03.001","article-title":"Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors","volume":"57","author":"Gonz\u00e1lez-Vicent","year":"2017","journal-title":"Leuk Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001620","article-title":"Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy","volume":"4","author":"Mariotti","year":"2020","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009240","article-title":"Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type","volume":"7","author":"Mehta","year":"2023","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01984-8","article-title":"Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation","volume":"58","author":"Pruitt","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24963","article-title":"Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012133","article-title":"Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT","volume":"8","author":"Sanz","year":"2024","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"blood.2023023697","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT","author":"Sanz","year":"2024","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","article-title":"Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide","volume":"2","author":"McCurdy","year":"2018","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"377.e371","DOI":"10.1016\/j.jtct.2023.03.028","article-title":"Impact of donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"29","author":"Mehta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27126","article-title":"Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age","volume":"99","author":"Saliba","year":"2024","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04865-0","article-title":"Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis","volume":"101","author":"de Lima","year":"2022","journal-title":"Ann Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01695-6","article-title":"Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT","volume":"57","author":"Danylesko","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-023-01421-9","article-title":"Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"16","author":"Ye","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-015-0507-z","article-title":"Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts","volume":"13","author":"Zhao","year":"2015","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.215","article-title":"Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis","volume":"51","author":"O\u2019Donnell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.3390\/jcm10132843","article-title":"Outcomes of bone marrow compared to peripheral blood for haploidentical transplantation","volume":"10","author":"Sharma","year":"2021","journal-title":"J Clin Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"782.e781","DOI":"10.1016\/j.jtct.2021.06.011","article-title":"Outcomes after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide: A systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimens and bone marrow with peripheral blood stem cell grafts","volume":"27","author":"Arcuri","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/bmt.2017.26","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.017","article-title":"Peripheral blood stem cells versus bone marrow for T cell-replete haploidentical transplantation with post-transplant cyclophosphamide in hodgkin lymphoma","volume":"25","author":"Mariotti","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1003.e1001","DOI":"10.1016\/j.jtct.2021.09.003","article-title":"Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"27","author":"Mehta","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0850-9","article-title":"Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia","volume":"34","author":"Nagler","year":"2020","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.05.017","article-title":"Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis","volume":"133","author":"Yu","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26627","article-title":"Human leukocyte antigen-haploidentical transplantation for relapsed\/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients\u2009\u226555\u2009years of age","volume":"97","author":"Baron","year":"2022","journal-title":"Am J Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003110","article-title":"Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide","volume":"4","author":"Solomon","year":"2020","journal-title":"Blood Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278993","article-title":"Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation","volume":"107","author":"Zou","year":"2022","journal-title":"Haematologica"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.05.001","article-title":"Treatment of hematological Malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide","volume":"24","author":"Munchel","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.03.002","article-title":"Antigen presentation by MHC-E: a putative target for vaccination","volume":"43","author":"Voogd","year":"2022","journal-title":"Trends Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe9057","article-title":"Natural killer cell receptors regulate responses of HLA-E-restricted T cells","volume":"6","author":"Sullivan","year":"2021","journal-title":"Sci Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.10.4951","article-title":"HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences","volume":"160","author":"Lee","year":"1998","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"601.e601","DOI":"10.1016\/j.jtct.2022.06.023","article-title":"Lineage-specific relapse prediction after haploidentical transplantation with post-transplant cyclophosphamide based on recipient HLA-B-leader genotype and HLA-C-group KIR ligand","volume":"28","author":"Solomon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1834449100","article-title":"HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes","author":"Pietra","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1159\/000538078","article-title":"Impacts of posttransplant cyclophosphamide dose on graft-versus-leukemia effects via HLA-B leader in HLA-haploidentical peripheral blood stem cell transplantation","author":"Moriguchi","year":"","journal-title":"Acta Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1279","article-title":"A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation","volume":"103","author":"Zino","year":"2004","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3374","article-title":"Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction","volume":"107","author":"Fleischhauer","year":"2006","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.042","article-title":"Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic Malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0170-5","article-title":"Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide","volume":"33","author":"Shimoni","year":"2019","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801489","article-title":"Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"202","author":"Willem","year":"2019","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.014","article-title":"Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen","volume":"17","author":"Ohata","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033871","article-title":"Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy","volume":"13","author":"Zou","year":"2022","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.765","article-title":"Donor KIR2DS1-mediated decreased relapse and improved survival depending on remission status at HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"26","author":"Ido","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"20.e1","DOI":"10.1016\/j.jtct.2021.09.019","article-title":"Effect of donor NKG2D polymorphism on relapse after haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Ido","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221112098","article-title":"A prospective study of an HLA-haploidentical peripheral blood stem cell transplantation regimen based on modification of the dose of posttransplant cyclophosphamide for poor prognosis or refractory hematological Malignancies","volume":"31","author":"Nakamae","year":"2022","journal-title":"Cell Transplant"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25826","article-title":"CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)","volume":"95","author":"Maffini","year":"2020","journal-title":"Am J Hematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01219-8","article-title":"Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Elmariah","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04031-4","article-title":"Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide","volume":"99","author":"Garnier","year":"2020","journal-title":"Ann Hematol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0183-8","article-title":"CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide","volume":"53","author":"Mussetti","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.01.007","article-title":"Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes","volume":"22","author":"Teofili","year":"2020","journal-title":"Cytotherapy"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.023.","article-title":"Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0665-3","article-title":"High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide","volume":"55","author":"Moiseev","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2024","journal-title":"Br J Haematol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological Malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B97","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","article-title":"HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome","volume":"43","author":"Nakamae","year":"2015","journal-title":"Exp Hematol"},{"key":"B98","first-page":"101","article-title":"Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation","volume-title":"The 63rd american society of hematology annual meeting and exposition","author":"McAdams","year":"2021"},{"key":"B99","article-title":"Interim results of a phase I\/II of intermediate-dose post-transplant cyclophosphamide after reduced intensity conditioned HLA-mismatched bone marrow transplantation for older or unfit patients","volume-title":"2024 tandem meetings transplantation & Cellular therapy meetings of ASTCT and CIBMTR","author":"McCurdy","year":"2024"},{"key":"B100","article-title":"Interim results of a phase I\/II of Intermediate-dose post-transplant cyclophosphamide after reduced intensity conditioned HLA-matched bone marrow transplantation for older or infirm patients","volume-title":"2024 tandem meetings transplantation & Cellular therapy meetings of ASTCT and CIBMTR","author":"Hyder","year":"2024"},{"key":"B101","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"500.e501","DOI":"10.1016\/j.jtct.2022.05.039","article-title":"Mycophenolate mofetil: A friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101078","article-title":"Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification","volume":"62","author":"Li","year":"2023","journal-title":"Blood Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000578","article-title":"Posttransplant cyclophosphamide and antithymocyte globulin versus posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution","volume":"205","author":"Makanga","year":"2020","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: A comparative study on behalf of the acute leukemia working party of the european society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B109","doi-asserted-by":"publisher","first-page":"928.e921","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/sci-2023-002","article-title":"Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"10","author":"Espinoza-Gutarra","year":"2023","journal-title":"Stem Cell Investig"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1082727","article-title":"Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy","volume":"14","author":"Leserer","year":"2023","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01574-0","article-title":"Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants","volume":"57","author":"Galli","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1403936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:27:14Z","timestamp":1718119634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1403936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2024.1403936"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1403936","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"article-number":"1403936"}}